Cargando…

Regulation of HHLA2 expression in kidney cancer and myeloid cells

BACKGROUND: The immune checkpoint HERV-H LTR-associating 2 (HHLA2) is expressed in kidney cancer and various other tumor types. Therapeutics targeting HHLA2 or its inhibitory receptor KIR3DL3 are being developed for solid tumors, including renal cell carcinoma (RCC). However, the regulation of HHLA2...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shigemura, Tomonari, Perrot, Nahuel, Huang, Zimo, Bhatt, Rupal S., Sheshdeh, Aseman Bagheri, Ahmar, Nourhan El, Ghandour, Fatme, Signoretti, Sabina, McDermott, David F., Freeman, Gordon J., Mahoney, Kathleen M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10605970/ https://www.ncbi.nlm.nih.gov/pubmed/37891555 http://dx.doi.org/10.1186/s12885-023-11496-9

Ejemplares similares

KIR3DL3-HHLA2 and TMIGD2-HHLA2 pathways: The dual role of HHLA2 in immune responses and its potential therapeutic approach for cancer immunotherapy
por: Li, Yang, et al.
Publicado: (2022)

Clinical Significance of the HHLA2 Protein in Hepatocellular Carcinoma and the Tumor Microenvironment
por: Luo, Min, et al.
Publicado: (2021)

HHLA2 Expression is Associated with Poor Survival in Patients with Hepatocellular Carcinoma
por: Xu, Yituo, et al.
Publicado: (2021)

Clinical Significance of the HHLA2 Protein in Hepatocellular Carcinoma and the Tumor Microenvironment [Corrigendum]
Publicado: (2021)

Overexpression and Role of HHLA2, a Novel Immune Checkpoint, in Colorectal Cancer
por: Kula, Agnieszka, et al.
Publicado: (2023)

Immunosuppression by Inflammation-Stimulated Amplification of Myeloid-Derived Suppressor Cells and Changes in Expression of Immune Checkpoint HHLA2 in Chronic Obstructive Pulmonary Disease
por: Xu, Lijuan, et al.
Publicado: (2023)

HHLA2 is a novel prognostic predictor and potential therapeutic target in malignant glioma
por: Qi, Yangzhi, et al.
Publicado: (2019)

HHLA2 predicts better survival and exhibits inhibited proliferation in epithelial ovarian cancer
por: Xu, Guocai, et al.
Publicado: (2021)

HHLA2 is a novel prognostic predictor and potential therapeutic target in malignant glioma
por: Qi, Yangzhi, et al.
Publicado: (2022)

Prognostic Significance of Potential Immune Checkpoint Member HHLA2 in Human Tumors: A Comprehensive Analysis
por: Wang, Ben, et al.
Publicado: (2019)

HHLA2 is expressed in pancreatic and ampullary cancers and increased expression is associated with better post-surgical prognosis
por: Boor, Patrick P. C., et al.
Publicado: (2020)

Prognostic value of HHLA2 expression in solid tumors: A meta-analysis based on the Chinese population
por: Zhang, Chuanmeng, et al.
Publicado: (2021)

HHLA2 Used as a Potential Prognostic and Immunological Biomarker and Correlated with Tumor Microenvironment in Pan-Cancer
por: Yang, Zeng, et al.
Publicado: (2022)

Comprehensive Analysis of HHLA2 as a Prognostic Biomarker and Its Association With Immune Infiltrates in Hepatocellular Carcinoma
por: Ding, Lin, et al.
Publicado: (2022)

Increased co-expression of stromal HHLA2 and fibroblast activation protein in upper tract urothelial carcinoma
por: Nishihara, Daisaku, et al.
Publicado: (2023)

Differential expression of c-Met between primary and metastatic sites in clear-cell renal cell carcinoma and its association with PD-L1 expression
por: Lalani, Aly-Khan A., et al.
Publicado: (2017)

HHLA2, a member of the B7 family, is expressed in human osteosarcoma and is associated with metastases and worse survival
por: Koirala, Pratistha, et al.
Publicado: (2016)

Overexpression of HHLA2, a member of the B7 family, is associated with worse survival in human colorectal carcinoma
por: Zhu, Ziwen, et al.
Publicado: (2018)

HHLA2 in intrahepatic cholangiocarcinoma: an immune checkpoint with prognostic significance and wider expression compared with PD-L1
por: Jing, Chu-Yu, et al.
Publicado: (2019)

Overexpression of HHLA2 in human clear cell renal cell carcinoma is significantly associated with poor survival of the patients
por: Chen, Lujun, et al.
Publicado: (2019)

Coexpression of HHLA2 and PD-L1 on Tumor Cells Independently Predicts the Survival of Spinal Chordoma Patients
por: Xia, Chao, et al.
Publicado: (2022)

HHLA2 predicts improved prognosis of anti-PD-1/PD-L1 immunotherapy in patients with melanoma
por: Huang, Fu-xue, et al.
Publicado: (2022)

HHLA2 promotes tumor progression by long non-coding RNA H19 in human gallbladder cancer
por: Zhang, Yizhou, et al.
Publicado: (2022)

High dose intermittent sorafenib shows improved efficacy over conventional continuous dose in renal cell carcinoma
por: Wang, Xiaoen, et al.
Publicado: (2011)

Circulating KIM-1 is a minimally invasive biomarker correlated with treatment response to nivolumab in patients with metastatic renal cell carcinoma
por: Xu, Wenxin, et al.
Publicado: (2023)

B7-H7 (HHLA2) inhibits T-cell activation and proliferation in the presence of TCR and CD28 signaling
por: Rieder, Sadiye Amcaoglu, et al.
Publicado: (2020)

Targeted immune epitope prediction to HHLA2 and MAGEB5 protein variants as therapeutic approach to related viral diseases
por: Achinko, Daniel A., et al.
Publicado: (2021)

Corrigendum: Coexpression of HHLA2 and PD-L1 on tumor cells independently predicts the survival of spinal chordoma patients
por: Xia, Chao, et al.
Publicado: (2023)

A Non-integrating Lentiviral Approach Overcomes Cas9-Induced Immune Rejection to Establish an Immunocompetent Metastatic Renal Cancer Model
por: Hu, Junhui, et al.
Publicado: (2018)

HHLA2 and PD-L1 co-expression predicts poor prognosis in patients with clear cell renal cell carcinoma
por: Zhou, Qiang-Hua, et al.
Publicado: (2020)

HHLA2 deficiency inhibits non‐small cell lung cancer progression and THP‐1 macrophage M2 polarization
por: Sun, Wenjie, et al.
Publicado: (2021)

The association of human endogenous retrovirus-H long terminal repeat-associating protein 2 (HHLA2) expression with gastric cancer prognosis
por: Shimonosono, Masataka, et al.
Publicado: (2018)

Correction: HHLA2 and PD-L1 co-expression predicts poor prognosis in patients with clear cell renal cell carcinoma
Publicado: (2020)

Over-Expression and Prognostic Significance of HHLA2, a New Immune Checkpoint Molecule, in Human Clear Cell Renal Cell Carcinoma
por: Zhang, Zhen, et al.
Publicado: (2020)

The combination of novel immune checkpoints HHLA2 and ICOSLG: A new system to predict survival and immune features in esophageal squamous cell carcinoma
por: Zhang, Chaoqi, et al.
Publicado: (2020)

H Long Terminal Repeat-Associating 2 (HHLA2) is a Biomarker of Advanced Stage Hepatocellular Carcinoma and Promotes Tumor Cell Development In Vitro
por: Luo, Min, et al.
Publicado: (2021)

The methyltransferase METTL3 promotes tumorigenesis via mediating HHLA2 mRNA m6A modification in human renal cell carcinoma
por: Zhu, Dawei, et al.
Publicado: (2022)

Resistance of Renal Cell Carcinoma to Sorafenib Is Mediated by Potentially Reversible Gene Expression
por: Zhang, Liang, et al.
Publicado: (2011)

Inhibition of ALK1 signaling with dalantercept combined with VEGFR TKI leads to tumor stasis in renal cell carcinoma
por: Wang, Xiaoen, et al.
Publicado: (2016)

Heterogeneous Expression of PD-L1, B7x, B7-H3, and HHLA2 in Pulmonary Sarcomatoid Carcinoma and the Related Regulatory Signaling Pathways
por: Wang, Feng, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_9e894tfvpfl3231166cdjmpaf1